Richard W. Joseph, MD, and Ira M. Klein, MD, MBA, FACP, provide their final thoughts about innovation and understanding how to use therapy based on appropriate endpoints, including how long to administer treatment.
Richard W. Joseph, MD, describes the strategy he uses to assess patients in the office, going beyond just radiographic changes.
Ira M. Klein, MD, MBA, FACP, and Richard W. Joseph, MD, discuss which end points are appropriate for clinical trials, drug approvals, and the patient’s perspective.
Ira M. Klein, MD, MBA, FACP, and Richard W. Joseph, MD, discuss how certain healthcare policy and programs can have a positive effect on innovation and on curtailing waste in the healthcare system.
In this segment, Peter Salgo, MD, and Ira M. Klein, MD, MBA, FACP, discuss the results of the recent CHAARTED trial, the factors that clinicians consider when making evidence-based treatment decisions, and the need for additional treatment options and clinical trial data.
Peter Salgo, MD, and Ira M. Klein, MD, MBA, FACP, discuss heterogeneous tumors in prostate cancer, the utilization of combination regimens, and the need for additional research within the field.
Peter Salgo, MD, and Ira M. Klein, MD, MBA, FACP, discuss the treatment of prostate cancer with androgen-deprivation therapy and note that additional research is necessary to help determine which patient populations are at highest risk for developing resistance following ADT.
During this opening segment of a one-on-one interview series, Peter Salgo, MD, discusses emerging diagnostic and prognostic biomarkers in prostate cancer with Ira M. Klein, MD, MBA, FACP. Dr Klein discusses how results of ongoing trials will be useful to help identify biomarkers to help providers track disease progression.
Ira Klein, MD, MBA, FACP, and Richard Joseph, MD discuss payers’ need for more evidence to develop coverage and reimbursement strategies for new agents.
Panelists discuss the differences between, and the alignment of comparative effectiveness research (CER) and innovation as processes for advancing care in cancer.
Peter Salgo, MD; Ira M. Klein, MD, MBA, FACP; and Richard W. Joseph, MD; discuss how different stakeholders view the value of innovative approaches in oncology.
Bryan Loy, MD, describes predictive value of diagnostic tests.